← Back to Search

Treatment for Pancreatic Cancer

N/A
Waitlist Available
Led By Raymond Wadlow, MD
Research Sponsored by Inova Health Care Services
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Summary

The purpose of this study is to collect information about treatment recommendations based on ctDNA testing and whether treatment changes based on ctDNA information result in better outcomes for patients with pancreatic cancer.

Eligible Conditions
  • Pancreatic Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Therapeutic procedure
Secondary study objectives
Frequency of positive SIGNATERA™ ctDNA testing
Overall survival of patients managed with SIGNATERA™ ctDNA data
Patient satisfaction of SIGNATERA™ ctDNA on treatment recommendations
+1 more

Find a Location

Who is running the clinical trial?

Inova Health Care ServicesLead Sponsor
72 Previous Clinical Trials
22,383 Total Patients Enrolled
Natera, Inc.Industry Sponsor
51 Previous Clinical Trials
41,697 Total Patients Enrolled
Raymond Wadlow, MDPrincipal InvestigatorInova Schar Cancer Institute
1 Previous Clinical Trials
10 Total Patients Enrolled
~0 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top